(0.27%) 5 201.90 points
(0.41%) 39 218 points
(0.18%) 16 331 points
(0.51%) $79.39
(4.07%) $2.28
(0.69%) $2 338.30
(2.74%) $28.36
(0.60%) $990.55
(-0.24%) $0.928
(-0.24%) $10.86
(-0.13%) $0.799
(0.87%) $92.54
Live Chart Being Loaded With Signals
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables...
Stats | |
---|---|
Today's Volume | 5 588.00 |
Average Volume | 9 618.00 |
Market Cap | 5.27B |
EPS | INR0 ( 2024-02-08 ) |
Next earnings date | ( INR0 ) 2024-05-27 |
Last Dividend | INR0.500 ( 2019-09-20 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 35.53 |
ATR14 | INR1.396 (0.42%) |
Volume Correlation
Kilitch Drugs (India) Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Kilitch Drugs (India) Correlation - Currency/Commodity
Kilitch Drugs (India) Financials
Annual | 2022 |
Revenue: | INR1.40B |
Gross Profit: | INR648.40M (46.45 %) |
EPS: | INR6.71 |
FY | 2022 |
Revenue: | INR1.40B |
Gross Profit: | INR648.40M (46.45 %) |
EPS: | INR6.71 |
FY | 2022 |
Revenue: | INR1.14B |
Gross Profit: | INR488.01M (42.72 %) |
EPS: | INR4.73 |
FY | 2021 |
Revenue: | INR685.23M |
Gross Profit: | INR312.16M (45.56 %) |
EPS: | INR2.37 |
Financial Reports:
No articles found.
Kilitch Drugs (India) Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
First Dividend | INR1.000 | 2010-10-14 |
Last Dividend | INR0.500 | 2019-09-20 |
Next Dividend | INR0 | N/A |
Payout Date | 2019-10-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | INR33.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.32 | -- |
Div. Sustainability Score | 3.63 | |
Div.Growth Potential Score | 3.48 | |
Div. Directional Score | 3.56 | -- |
Year | Amount | Yield |
---|---|---|
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR0.500 | 0.59% |
2019 | INR0.500 | 0.31% |
2020 | INR0 | 0.00% |
2021 | INR0 | 0.00% |
2022 | INR0 | 0.00% |
2023 | INR0 | 0.00% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SOUTHBANK.NS | Dividend Junior | 2023-08-17 | Sporadic | 25 | 0.42% | |
MOLDTECH.NS | Dividend Knight | 2023-09-18 | Annually | 9 | 1.62% | |
HEG.NS | Dividend Junior | 2023-08-24 | Annually | 23 | 1.70% | |
BHARATRAS.NS | Dividend Junior | 2023-09-06 | Annually | 17 | 0.01% | |
RAMCOCEM.NS | Dividend Junior | 2023-08-02 | Annually | 23 | 0.21% | |
KKCL.NS | Dividend Knight | 2023-05-11 | Semi-Annually | 19 | 1.67% | |
ENIL.NS | Dividend Junior | 2023-09-15 | Annually | 12 | 0.39% | |
ALICON.NS | Dividend Junior | 2023-09-13 | Annually | 18 | 0.25% | |
SWARAJENG.NS | Dividend Knight | 2023-07-06 | Annually | 23 | 2.81% | |
NDRAUTO.NS | Dividend Junior | 2023-07-12 | Annually | 4 | 0.59% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0940 | 1.500 | 8.12 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.0916 | 1.500 | -0.0933 | -0.140 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 4.20 | 1.000 | 9.56 | 9.56 | [3 - 30] |
operatingCashFlowPerShareTTM | 4.15 | 2.00 | 8.62 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 4.15 | 2.00 | 7.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.486 | 1.000 | 5.24 | 5.24 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.158 | 1.000 | 8.85 | 8.85 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 3.63 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 36.81 | 1.000 | 6.38 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0916 | 2.50 | -0.0600 | -0.140 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 4.15 | 2.00 | 8.62 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 4.15 | 2.00 | 8.62 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.879 | 1.500 | 7.47 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0430 | 1.000 | -1.424 | 0 | [0.1 - 0.5] |
Total Score | 3.48 |
Kilitch Drugs (India)
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators